GH Research is a holding company. Through its subsidiary, Co. is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. Co.'s initial focus is on developing its novel and proprietary 5-Methoxy-N,N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Co.'s portfolio includes GH001, Co.'s proprietary inhalable 5-MeO-DMT product candidate which is delivered via a vaporization device produced by a third party, and GH002, Co.'s proprietary injectable 5-MeO-DMT product candidate. The GHRS average annual return since 2021 is shown above.
The Average Annual Return on the GHRS average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether GHRS average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the GHRS average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|